Table 3.
Ongoing clinical trials for HPV-positive HNSCC.
| ID | Phase | N | Inclusion criteria | Interventions | Immunotherapy targets | Main outcome |
|---|---|---|---|---|---|---|
| NCT03383094 | II | 114 | Advanced/Intermediate-Risk p16+HNSCC | Pembrolizumab + RT vs Cisplatin + RT | PD-1 | PFS |
| NCT03578406 | I | 20 | HPV+R/M HNSCC | HPV E6-specific TCR-T cells | Engineered T cells | MTD |
| NCT02002182 | II | 15 | HPV+HNSCC | ADXS 11-001 vs Control | Vaccine | HPV-Specific T Cell Response Rate |
| NCT03618134 | I/II | 82 | HPV+OPSCC | SBRT + Durvalumab + surgery vs
SBRT + Durvalumab + Tremelimumab + surgery |
PD-L1, CTLA-4 | Incidence of adverse events, PFS |
| NCT04260126 | II | 96 | HPV16+R/M HNSCC | Pembrolizumab+PDS0101 | PD-1, T-cell immunotherapy |
ORR |
| NCT03162224 | I/II | 35 | HPV+R/M HNSCC | MEDI0457, Durvalumab | Vaccine, PD-L1 |
Number of patients with changes in ECG, Occurrence of SAEs |
This table contains only clinical trials registered on the ClinicalTrials,gov for HPV-positive HNSCC that are in progressing and do not include terminated or completed.
RT, Radiation therapy; HNSCC, Head and neck squamous cell carcinoma; PFS, Progression-free survival; R/M, Recurrence/metastasis; MTD, The Maximum Tolerated Dose; OPSCC, Oropharyngeal squamous cell carcinoma; SBRT, Stereotactic Body Radiotherapy; ORR, Objective Response Rate; ECG, Electrocariogram; SAEs, Serious adverse events; HPV, Human papillomavirus.